Study shows link between metabolic syndrome and risk of cognitive disorders

A study presented at the European Academy of Neurology Congress in Amsterdam has shown that obesity alone is not a risk factor for cognitive disorders, but commonly associated co-morbidities such as diabetes, high blood pressure, and metabolic disorders are. Dementia diseases in patients who suffer from diabetes are often treated inadequately, a new research paper reveals.

It has long been supposed that patients with metabolic syndrome are more likely to suffer from cognitive impairment - and to a greater extent. Reasons are thought to include chronic inflammatory processes which can induce neuroinflammatory and neurodegenerative changes. Whether obese individuals without risk factors such as diabetes mellitus, metabolic disorders and the presence of albumin in the urine have an increased risk of cognitive impairment is still little researched.

A group of Israeli researchers analyzed 60 obese individuals with a body mass index of over 30 in two groups: the members of the first group had a maximum of one component of metabolic syndrome, while those in the second group presented two or more. The Montreal Cognitive Assessment Score (MOCA) was used to determine cognitive dysfunction, if any.

Obesity alone not a risk factor for cognitive disorders

The results of the study presented at the 3rd Congress of the European Academy of Neurology (EAN) in Amsterdam clearly showed that while cognitive ability is not necessarily determined by overweight, it is influenced by the risk factors that go with it. "There is a clear association between metabolic risk factors and cognitive impairment," summarized the study's authors Dr. Radi Shahien and Dr. Aleh Abu Salach from the Ziv Medical Centre in Safed, Israel. Of the 30 patients with several components of metabolic syndrome, 13 percent had dementia, 51 percent milder forms of cognitive impairment and 36 percent showed no signs of cognitive dysfunction. In the control group of metabolically healthy obese individuals, more than 90 percent had a normal cognitive score, 7 percent showed mild impairment and the remainder had already developed dementia.

Age and abdominal girth the main risk factors

Looking at the results in detail, it emerged that abdominal girth and age were the greatest risk factors. That said, there was also a strong correlation between cognitive score, and high blood pressure and liver stiffness. "Additional studies need to be undertaken to show whether treatment of individual factors in metabolic syndrome can improve cognitive function," Dr. Shahien added.

Dementia treatment worse among diabetes patients

Another study presented at the EAN Congress in Amsterdam examined a different correlation. A research group from the Karolinska Institute in Stockholm wanted to investigate the clinical characteristics of diabetes mellitus in a large cohort of dementia patients. The study conducted by Prof Dorota Religa and Dr Juraj Senik included 29,630 patients with cognitive impairments, 4,881 of whom were also diagnosed with diabetes mellitus.

Patients who were younger when they received their dementia diagnosis were more likely to suffer from diabetes, with more men affected than women. Vascular dementia or a mixed form of vascular dementia and Alzheimer's disease were also more common in diabetes patients. On the other hand, Lewy body dementia and Parkinson's dementia were both less common among diabetes patients.

The study also found that patients with diabetes not only received less treatment with antidepressants but also obtained significantly less Alzheimer's medication. "This could show less optimal dementia treatment among diabetes patients than in others," suggested Prof. Dorota Religa, before issuing a call for additional studies to focus on these aspects. "We have further developed the study and the manuscript was accepted for publication in Diabetes Care, the official journal of the American Diabetes Association.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation